Literature DB >> 25498455

Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.

Rosella Famà1, Riccardo Bomben2, Silvia Rasi1, Michele Dal Bo2, Carmela Ciardullo1, Sara Monti1, Francesca Rossi2, Tiziana D'Agaro2, Antonella Zucchetto2, Valter Gattei2, Gianluca Gaidano1, Davide Rossi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25498455     DOI： 10.1182/blood-2014-08-592725

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  The molecular pathogenesis of chronic lymphocytic leukaemia.

Authors:  Giulia Fabbri; Riccardo Dalla-Favera
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

2.  Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Authors:  Inhye E Ahn; Chingiz Underbayev; Adam Albitar; Sarah E M Herman; Xin Tian; Irina Maric; Diane C Arthur; Laura Wake; Stefania Pittaluga; Constance M Yuan; Maryalice Stetler-Stevenson; Susan Soto; Janet Valdez; Pia Nierman; Jennifer Lotter; Liqiang Xi; Mark Raffeld; Mohammed Farooqui; Maher Albitar; Adrian Wiestner
Journal:  Blood       Date:  2017-01-03       Impact factor: 22.113

Review 3.  Targeted therapies in CLL: mechanisms of resistance and strategies for management.

Authors:  Jennifer A Woyach; Amy J Johnson
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

4.  Unmask the genetic backbone of ibrutinib-relapsed chronic lymphocytic leukemia progression and Richter transformation.

Authors:  Wei-Ge Wang; Xiao-Yan Zhou; Xiao-Qiu Li
Journal:  Ann Transl Med       Date:  2018-06

Review 5.  Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.

Authors:  Ayed O Ayed; Sameer A Parikh
Journal:  Leuk Lymphoma       Date:  2017-11-08

Review 6.  Second-generation inhibitors of Bruton tyrosine kinase.

Authors:  Jingjing Wu; Christina Liu; Stella T Tsui; Delong Liu
Journal:  J Hematol Oncol       Date:  2016-09-02       Impact factor: 17.388

Review 7.  Precision Medicine Management of Chronic Lymphocytic Leukemia.

Authors:  Riccardo Moia; Andrea Patriarca; Mattia Schipani; Valentina Ferri; Chiara Favini; Sruthi Sagiraju; Wael Al Essa; Gianluca Gaidano
Journal:  Cancers (Basel)       Date:  2020-03-10       Impact factor: 6.639

Review 8.  Promises and pitfalls of targeted agents in chronic lymphocytic leukemia.

Authors:  Thomas E Lew; Mary Ann Anderson; John F Seymour
Journal:  Cancer Drug Resist       Date:  2020-05-23

9.  A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.

Authors:  Lisa S Chen; Prithviraj Bose; Nichole D Cruz; Yongying Jiang; Qi Wu; Philip A Thompson; Shuju Feng; Michael H Kroll; Wei Qiao; Xuelin Huang; Nitin Jain; William G Wierda; Michael J Keating; Varsha Gandhi
Journal:  Blood       Date:  2018-09-25       Impact factor: 25.476

Review 10.  The clinical implications of gene mutations in chronic lymphocytic leukaemia.

Authors:  Davide Rossi; Gianluca Gaidano
Journal:  Br J Cancer       Date:  2016-03-31       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.